scholarly journals The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates.

1993 ◽  
Vol 92 (6) ◽  
pp. 2577-2586 ◽  
Author(s):  
R Balena ◽  
B C Toolan ◽  
M Shea ◽  
A Markatos ◽  
E R Myers ◽  
...  
1992 ◽  
Vol 50 (1) ◽  
pp. 11-13 ◽  
Author(s):  
Heikki Kröger ◽  
Ilkka Arnala ◽  
Esko M. Alhava

2019 ◽  
Vol 20 (3) ◽  
pp. 354-365 ◽  
Author(s):  
Tiantian Wang ◽  
Hongchen He ◽  
Shaxin Liu ◽  
Chengsen Jia ◽  
Ziyan Fan ◽  
...  

Autophagy is a process the primary role of which is to clear up damaged cellular components such as long-lived proteins and organelles, thus participating in the conservation of different cells. Osteoporosis associated with aging is characterized by consistent changes in bone metabolism with suppression of bone formation as well as increased bone resorption. In advanced age, not only bone mass but also bone strength decrease in both sexes, resulting in an increased incidence of fractures. Clinical and animal experiments reveal that age-related bone loss is associated with many factors such as accumulation of autophagy, increased levels of reactive oxygen species, sex hormone deficiency, and high levels of endogenous glucocorticoids. Available basic and clinical studies indicate that age-associated factors can regulate autophagy. Those factors play important roles in bone remodeling and contribute to decreased bone mass and bone strength with aging. In this review, we summarize the mechanisms involved in bone metabolism related to aging and autophagy, supplying a theory for therapeutic targets to rescue bone mass and bone strength in older people.


2017 ◽  
Vol 20 (1) ◽  
pp. 25
Author(s):  
MK Jindal ◽  
OP Lakhwani ◽  
SK Kapoor ◽  
RK Chandoke ◽  
Omkar Kaur ◽  
...  

Hepatology ◽  
2002 ◽  
Vol 36 (4) ◽  
pp. 895-903 ◽  
Author(s):  
Maureen M. J. Guichelaar ◽  
Michael Malinchoc ◽  
Jean Sibonga ◽  
Bart L. Clarke ◽  
J. Eileen Hay

2020 ◽  
Vol 2020 ◽  
pp. 1-12
Author(s):  
Pan Sun ◽  
Yuanyuan Zhang ◽  
Zhenpu Wei ◽  
Zhiqiang Wang ◽  
Shiming Guo ◽  
...  

Senile osteoporosis (SOP) is a common disease that has decreased bone strength as its main symptom. There is currently no medication that can treat SOP, and traditional Chinese medicine has advantages in slowing down bone aging. The present study aimed to observe the effects of Qing’e decoction on leptin, leptin receptor, sex hormone, and biochemical markers of bone metabolism in naturally aging rats and to explore its mechanism in regulating bone metabolism. The results revealed that, with the increase in age, the bone mineral density (BMD), bone strength, bone trabecula sparse, serum levels of leptin receptor (LEP-R), estradiol (E2), testosterone (T), core binding-factor α-1 (Cbfα-1), collagen-I (COL-I) and osteocalcin (OC), and the mRNA levels of leptin (LEP) and LEP-R in bone tissue decreased, while serum LEP levels increased in the female and male NS groups. The serum levels of LEP, LEP-R, E2, T, osteoprotegerin, Cbfα-1, COL-I, OC and bone alkaline phosphatase, and the mRNA levels of LEP and LEP-R in bone tissue in the female and male QED groups were higher than those in the same age and sex NS group, while the BMD, bone trabecular area percentage, maximum load, and maximum stress in the female and male QED groups were significantly higher than those in the same age and sex NS group. In conclusion, with the increase in age, the bone quality of naturally aging rats decreased gradually. Qing’e decoction can regulate the bone metabolism and increase the bone quality and delay bone aging, which may be achieved by increasing sex hormone, LEP, and LEP-R levels.


2006 ◽  
Vol 84 (5) ◽  
pp. 1138-1146 ◽  
Author(s):  
D. T. Shaw ◽  
D. W. Rozeboom ◽  
G. M. Hill ◽  
M. W. Orth ◽  
D. S. Rosenstein ◽  
...  

2019 ◽  
Vol 8 (12) ◽  
pp. 2027 ◽  
Author(s):  
Annelies De Maré ◽  
Anja Verhulst ◽  
Etienne Cavalier ◽  
Pierre Delanaye ◽  
Geert J. Behets ◽  
...  

Mounting evidence indicates that sclerostin, a well-known inhibitor of bone formation, may qualify as a clinically relevant biomarker of chronic kidney disease-related mineral and bone disorder (CKD-MBD), including abnormal mineral and bone metabolism and extraskeletal calcification. For this purpose, in this study we investigate the extent to which circulating sclerostin, skeletal sclerostin expression, bone histomorphometric parameters, and serum markers of bone metabolism associate with each other. Bone biopsies and serum samples were collected in a cohort of 68 end-stage kidney disease (ESKD) patients. Serum sclerostin levels were measured using 4 different commercially available assays. Skeletal sclerostin expression was evaluated on immunohistochemically stained bone sections. Quantitative bone histomorphometry was performed on Goldner stained tissue sections. Different serum markers of bone metabolism were analyzed using in-house techniques or commercially available assays. Despite large inter-assay differences for circulating sclerostin, results obtained with the 4 assays under study closely correlated with each other, whilst moderate significant correlations with skeletal sclerostin expression were also found. Both skeletal and circulating sclerostin negatively correlated with histomorphometric bone and serum parameters reflecting bone formation and turnover. In this study, the unique combined evaluation of bone sclerostin expression, bone histomorphometry, bone biomarkers, and serum sclerostin levels, as assessed by 4 different assays, demonstrated that sclerostin may qualify as a clinically relevant marker of disturbed bone metabolism in ESKD patients.


Sign in / Sign up

Export Citation Format

Share Document